Improvement of vaginal probiotics Lactobacillus crispatus on intrauterine adhesion in mice model and in clinical practice.

2023-03-22
BMC microbiology 23(1)
- Fei Wu
- Yao Kong
- Wenjie Chen
- Dingfa Liang
- Qin Xiao
- Lijuan Hu
- Xiao Tan
- Jing Wei
- Yujuan Liu
- Xiaorong Deng
- Zhaoxia Liu
- Tingtao Chen

PubMed: 36949381
DOI: 10.1186/s12866-023-02823-y

Study Design

Type: Randomized Controlled Trial (RCT)
Population: patients with intrauterine adhesion after transcervical resection of adhesion
Methods: randomized controlled trial to compare the therapeutic effect of L. crispatus with estrogen after transcervical resection of adhesion (TCRA)
Funding: Unclear

Background

Intrauterine adhesion (IUA) is a frequent acquired endometrial condition, for which there is no effective preventive or treatment. Previous studies have found that vaginal microbiota dysregulation is closely related to endometrial fibrosis and IUA. Therefore, we wondered whether restoration of vaginal microbiota by vaginal administration of L. crispatus could prevent endometrial fibrosis and ameliorate IUA.

Results

First, we created a mechanically injured mouse model of IUA and restored the mice's vaginal microbiota by the addition of L. crispatus convolvulus. The observations suggested that intrauterine injections of L. crispatus significantly decreased the degree of uterine fibrosis, the levels of IL-1β and TNF-α in blood, and downregulated the TGF-β1/SMADs signaling pathway in IUA mice. A therapy with L. crispatus considerably raised the abundance of the helpful bacteria Lactobacillus and Oscillospira and restored the balance of the vaginal microbiota in IUA mice, according to high-throughput sequencing. Then we conducted a randomized controlled trial to compare the therapeutic effect of L. crispatus with estrogen after transcervical resection of adhesion (TCRA). And the results showed that vaginal probiotics had a better potential to prevent intrauterine adhesion than estrogen.

Conclusions

This study confirmed that L. crispatus could restore vaginal microbiota after intrauterine surgery, inhibit endometrial fibrosis, and finally play a preventive and therapeutic role in IUA. At the same time, it is a new exploration for the treatment of gynecological diseases with vaginal probiotics.

Clinical trial registration

http://www.chictr.org.cn/ , identifier (ChiCTR1900022522), registration time: 15/04/2019.